Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMC-TR1
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IMC-TR1 (also known as LY3022859) is a human monoclonal antibody that targets the transforming growth factor beta type II receptor (TGF-beta RII or TGFBR2). It acts as an antagonist of this receptor, thereby inhibiting TGF-beta signaling. The drug was developed for its potential antineoplastic activity, particularly in the treatment of advanced solid tumors. Preclinical studies showed promising responses in mouse models of breast and colon cancer. In clinical development, it was evaluated in phase 1 trials for patients with advanced solid tumors; however, dose escalation beyond 25 mg was considered unsafe due to cytokine release syndrome despite prophylaxis. The maximum tolerated dose (MTD) was not determined and no further development has been reported since 2016[1][2][3][5].
- Other names
- anti-TGF-beta RII monoclonal antibody IMC-TR1LY3022859LY-3022859LY 3022859
02
Targets
TGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on IMC-TR1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMC-TR1.